For instance, the patient with anti-GFAP antibodies presented with encephalopathy accompanied by movement disorders and hyperintensities in the basal ganglia, responding to corticosteroids while the patient with anti-LGI1 antibodies presented with encephalitis featuring focal seizures and responding to plasmapheresis and rituximab.23-25. Here, LGI1 is linked to movement disorder.